Phase 1 Study to Evaluate the Absorption, Metabolism, and Excretion of Alimatravir (MK-8527), a Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults Without HIV

Conference Reports for NATAP

IDSA
ID Week 2026
October 21-24
Washington, DC


Phase 1 Study to Evaluate the Absorption, Metabolism, and Excretion of Alimatravir (MK-8527), a Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults Without HIV

	IDSA 2026 Wash DC Oct 21-24 CROI2026: MK-8527 Phase 3 Dose Selection for Monthly Oral HIV-1 Pre-exposure Prophylaxis Oral Monthly PrEP MK-8527 studies